Combination of CFTR gene mutation and autoimmune pancreatitis presenting as necrotizing pancreatitis.
Henna Patel,J. Levine,Toba A. Weinstein
DOI: https://doi.org/10.1097/MPA.0b013e31824993b5
2012-08-01
Pancreas
Abstract:To the Editor: Pancreatitis associated with decreased cystic fibrosis transmembrane conductance regulator (CFTR) function and autoimmune pancreatitis (AIP) are two separate and rare conditions that cause acute and chronic pancreatitis in the pediatric population.1,2 Autoimmune pancreatitis is an uncommon cause of chronic pancreatitis in children, typically presenting with relatively mild symptoms with an autoimmune association. There are multiple genetic etiologies associated with pancreatitis, including CFTR gene mutations. The CFTR gene mutations have never been confirmed to be related to the degree or intensity of the symptoms of pancreatitis, although some have been linked with the disease. Identifying gene mutations may help recognize those patients who are at risk of developing recurrent and severe pancreatitis. We report the first case of a child who presented with necrotizing pancreatitis found to have a CFTR gene mutation and features of AIP. A 13-year-old boy presented with acute epigastric pain, fever, and vomiting. On physical examination, the patient was febrile with a distended abdomen and marked epigastric tenderness. He had an elevated white blood cell count (neutrophil predominant). Serum amylase and lipase were 858 U/L (25Y123 U/L) and 2528 U/L (7Y60 U/L), respectively. The patient had a pleural effusion on chest radiography. The abdominal ultrasound showed moderate ascites with a well-distended gallbladder, no gallstones, and no gallbladder wall thickening. The pancreas appeared enlarged and heterogeneous, with septations and debris, suggestive of pancreatitis with an infectious component. There was no family history of pancreatic disease or cystic fibrosis (CF). Computed tomographic (CT) scan and magnetic resonance imaging findings showed an abnormal pancreas with severe phlegmon and suggestion of necrotic tissue. The patient was diagnosed as having necrotizing pancreatitis, and by the eighth hospital day, the patient had clinically improved. Dietary restrictions were modified, and he was advanced to a low-fat diet and discharged home. Genetic testing revealed a heterozygous presence of R75Q variant CFTR gene. Despite compliance with a low-fat diet and use of pancreatic enzyme replacement, the patient had eight hospitalizations for pancreatitis during the next 3 years, which prompted further investigation. Endoscopic retrograde cholangiopancreatography showed a small and fibrotic major papilla, a stricture in the supra-ampullary portion of the pancreatic duct, but no pancreatic divisum. The patient had a positive antinuclear antibody and an IgG4 level of 332 mg/dL (normal range, 0.3Y 111.0 mg/dL). The diagnosis of AIP was made based on these findings. The patient and his family refused a pancreatic biopsy. Steroid therapywasdiscussed,however,not instituted because the patient was responsive to conservative medical management. The AIP is correlated with specific clinical, laboratory, radiographic, and histopathologic findings. Clinical findings consist of obstructive jaundice, weight loss, abdominal pain, nausea, and vomiting. Radiographic findings supporting the diagnosis of AIP include magnetic resonance imaging or CT scans showing a diffuse sausage-shaped enlargement of the pancreas.6 An irregular narrow pancreatic duct and/or multiple strictures without upstream ductal dilatation on pancreatic imaging are suggestive of AIP. In our patient, the initial CT scan revealed phlegmon and necrotic changes but did not visualize the pancreatic duct, leading to the diagnosis of necrotizing pancreatitis. The subsequent endoscopic retrograde cholangiopancreatography found the pancreatic duct to be difficult to cannulate with a stricture in the supra-ampullary portion without ductal dilation. Based on these findings, serological testing for AIP was obtained. Elevated levels of IgG4 are felt to be the best markers of AIP, with a sensitivity of 73.3% and a specificity of 95.1%. Despite lack of histology and the decision to hold on systemic steroid therapy, given the clinical, radiographic, and laboratory findings, our patient met the criteria for AIP based on the criteria stated by the Japanese Pancreas Society. In children, CF associated with CFTR gene mutations is the most common cause of chronic and recurrent pancreatitis. A recent study of pancreatic-sufficient CF patients determined that patients with genotypes associated with mild phenotypic effects (at least one CFTR mutation) had a greater risk of developing pancreatitis than patients with more severe phenotypes. The CFTR gene, R75Q, found in our patient was tested as a part of a multicenter study. Patients with a combined mutation in both SPINK-1 and CFTR R75Q were found to have a higher risk of pancreatitis. The conclusions drawn from this study were that the combination of a CFTR gene R75Q and SPINK-1 mutation increases the risk of chronic pancreatitis in a multiplicative manner.13 One could speculate from this study that the presence of the CFTR R75Q gene may carry a more significant and severe risk of pancreatitis in the setting of other risk factors or underlying etiologies, such as hereditary pancreatitis, pancreatic duct divisum, or AIP. In our patient with AIP, the presence of the CFTR gene mutation leads us to believe the severity of our patient’s attacks, specifically, the development of necrotizing pancreatitis, is a result of this combination.